Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery
• TIL Therapy Development
  • Special TIL Therapy Development

Virus-based Vaccine Boosting CAR-T Cell Solutions

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs is a world leader in the field of CAR-T generation and vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best virus-based vaccine-boosting CAR-T services for the treatment of solid tumors. We guarantee the finest results for our customers all over the world.

Introduction to Virus-based Vaccine Boosting CAR-T Therapy

A virus vaccine is designed by introducing tumor antigens into the human body as a vaccination to overcome the immunosuppressive state caused by the tumor, enhance the immunogenicity, and induce the body's cellular and humoral immune response to fight or eliminate the tumor. In the treatment of solid tumors, CAR-T still uses tumor-associated antigens as the target. At present, CAR-T can identify and target more than ten kinds of solid tumors, such as lung cancer, breast cancer, and pancreatic cancer. However, there are significant difficulties in the CAR-T treatment of solid tumors. The main challenges are (1) Lack of tumor-specific antigen due to tumor heterogeneity; and (2) Inhibition of tumor microenvironment. Therefore, many researchers began to try to combine CAR-T therapy with other strategies to treat tumors, hoping to eliminate or reduce the potential defects caused by CAR-T itself, improve the therapeutic effect, or reduce the original side effects. Recent studies have shown that the combination of vaccines and CAR-T cells can achieve a dual strategy of optimizing tumor tropism and specificity, which is an ideal group against solid tumors.

Fig.1 Amph-FITC Ligands Boost The Anti-tumor Activity of Bispecific CAR-T Cells.¹

Virus-based Vaccine Boosting CAR-T Cell Solutions

The Creative Biolabs research team has been focused on both tumor vaccines and CAR-T therapy for years. Currently, We have developed a virus-based vaccine boosting CAR-T cell therapy platform that can increase the number of CAR-T cells with anti-tumor activity in the body by at least 20-fold and significantly reduce the side effects of the vaccine. In our labs, we designed the virus vaccine as a novel CAR T ligand that can be transported to lymph nodes and bind the surface of antigen-presenting cells, thereby activating CAR T in the native lymph node microenvironment.

By establishing immunofunctional mouse tumor models, we found that this virus vaccine can enhance and induce large amounts of CAR-T amplification, increase donor cell versatility, and enhance anti-tumor efficacy. Up to now, we have extended multiple flexible strategies to existing CAR-T designs to enhance anti-solid tumor efficacy.

• Applicable to a variety of solid tumors
• Trigger the involvement of the endogenous immune system
• Avoid escape of antigen-negative tumors
• Promotes the recruitment of dendritic cells (DC) to tumors
• Enhance heterogeneous tumor control
• The number of CAR T cells increased 100-fold
• A variety of antitumor functions promote 3 ~ 5 times
• The tumor disappeared completely in 50% of the model mice

Fig. 2 Vaccine Boosting Enables CAR T-cells to Elicit Endogenous T-cell Responses in Multiple Tumor Models.²

Chief Solutions

We modified virus-specific T cells (VST) with tumor-specific CAR, and the immunogenicity of these viruses can be used for the treatment of solid tumors.

• CAR-modified VZV-specific T Cells (CAR-VZVSTs) Solutions

In our labs, we have generated GMP-compliant GD2 CARs and then modified them with live attenuated VZV vaccines. Peripheral blood mononuclear cells are stimulated by using overlapping peptide libraries covering selected VZV antigens. Finally, they are tested for their ability to recognize and kill target cells expressing GD2 and VZV antigens.

• CAR-modified CMV-specific T Cells (CAR-CMVSTs) Solutions

We have developed a novel combination immunotherapy in which cytomegalovirus (CMV) pp65-specific T cells are selected and amplified for in vitro modification of CAR targeting CD19. our data have indicated that these CMV-CD19 CAR T cells can stimulate natural CMV-specific T cell receptor (TCR) expansion in vivo by using the CMV vaccine.

• CAR-modified gp100-specific T Cells (CAR-gp100STs) Solutions

In Creative Biolabs, we generated CAR-gp100STs constructs by lentivirus transduction of gp100-specific T-cell receptor (TCR) and construction of specific chimeric antigen receptor (CAR) mRNA. These antigen-specific receptors can be functionally combined through different methods to introduce each receptor into the same T cell, which opens up new possibilities and opportunities for cancer immunotherapy.

Creative Biolabs has won a good reputation among our worldwide customers for accomplishing numerous challenging virus-based vaccine-boosting CAR-T cell projects. We have experienced experts and advanced platforms that can provide excellent services. If you are interested in our services, please contact us for more details.

References

1. Ma, Leyuan, et al. "Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor." Science 365.6449 (2019): 162-168.
2. Ma, Leyuan, et al. "Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity." Cell 186.15 (2023): 3148-3165.